Michael Wang on the Reversible BTK Inhibitor for Previously Treated MCL
The FDA recently granted accelerated approval to pirtobrutinib (Jaypirca), a reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a BTK inhibitor. In this exclusive MedPage Today video, Michael Wang, MD, of the University of Texas MD […]
Novel BTK Inhibitor Looks Good for Sjogren’s Syndrome
PHILADELPHIA — Remibrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, appeared effective in reducing signs of Sjogren’s syndrome in a randomized, placebo-controlled trial. Scores on the EULAR Sjogren’s Syndrome Activity Index (ESSDAI), a comprehensive measure of Sjogren’s severity, fell by 2.86 points with the oral drug relative to placebo during the 24-week trial, according to […]